Unique ID issued by UMIN | UMIN000002310 |
---|---|
Receipt number | R000002816 |
Scientific Title | Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis. |
Date of disclosure of the study information | 2009/08/31 |
Last modified on | 2014/03/27 18:02:31 |
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients. (GBCRG-2surg-01)
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients. (GBCRG-2surg-01)
Japan |
Breast cancer
Endocrine surgery | Breast surgery |
Malignancy
NO
To evaluate the efficacy and safety of adjuvant chemotherapy combined with docetaxel and cyclophosphamide for breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Safety
completion rate
Disease free survival
Overall survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
four cycles of therapy, administered every 3 weeks.
Docetaxel (75 mg/m2) and Cyclophosphamide (600 mg/m2) are administered by intravenous infusion on day 1 in eacn cycle.
20 | years-old | <= |
70 | years-old | >= |
Female
1) Histologically diagnosed breast cancer without lymph node metastasis or with three and under lymph node metastasis.
2)Age 20 to 70 years
3)ECOG PS 0 to 2
4)Previous endocrine therapy or chemotherapy for breast cancer.
5)Required baseline laboratory parameters
6)Without severe complications,ischemia attack, uncontrolled congestive heart failure
7)Written informed consent
1)Patients who received previous endocrine therapy or chemotherapy
2)Severe drug allergic history
3)Inflammatory breast cancer
4)Bilateral breast cancer in same time
5)Severe complications
6)Active double cancer
7)Inflammation with fever up
8)Neurological problem
9)Pleural effusion or pericardial effusion
10)Symptomatic brain metastasis
11)Pregnancy
12)Severe edema
13)Interstitial lung disease, pulmonary fibrosis
14)Psychiatric disease
15)Doctors decision for excluion
16)Low risk in St. Gallen Conferences 2007
17)16 weeks or more after operation
90
1st name | |
Middle name | |
Last name | Nana Rokutanda |
Gunma University Graduate School of Medicine
Thoracic Visceral Organ Surgery
3-39-15 Showa-machi, Maebashi-city, Gunma, 371-8511, Japan
027-220-8245
nana.rokutanda@gmail.com
1st name | |
Middle name | |
Last name | Nana Rokutanda |
Gunma Breast Cancer Research Group 2 surgery (GBCRG-2surg) 01
Secretariat Division (Department of Thoracic Visceral Organ Surgery , Gunma University Graduate Scho
3-39-15 Showa-machi, Maebashi-city, Gunma, 371-8511, Japan
027-220-8245
nana.rokutanda@gmail.com
Gunma Breast Cancer Research Group 2 surgery
Department of Thoracic Visceral Organ Surgery ,
Gunma University Graduate Schol of Medicine
Self funding
NO
2009 | Year | 08 | Month | 31 | Day |
Unpublished
No longer recruiting
2009 | Year | 06 | Month | 24 | Day |
2009 | Year | 07 | Month | 01 | Day |
2016 | Year | 12 | Month | 01 | Day |
2016 | Year | 12 | Month | 01 | Day |
2009 | Year | 08 | Month | 09 | Day |
2014 | Year | 03 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002816